New combo therapy targets tough bile duct cancer
Disease control
Recruiting now
This study tests a combination of two drugs (pemigatinib and durvalumab) in people with advanced bile duct cancer that has a specific change in the FGFR-2 gene and has not responded to prior treatment. The goal is to see if this combination can shrink tumors or slow the cancer. A…
Phase: PHASE2 • Sponsor: Mehmet Akce • Aim: Disease control
Last updated May 12, 2026 13:39 UTC